VOLUME 4 STERRRAD SUPERIORITY AFACTSHEET BY

# • The Importance of Instrument Validation

 Despite all efforts against healthcare-associated infections (HAIs), 22% of all surgical site infections (SSIs) are related to device reprocessing;<sup>1-5</sup> a significant proportion is considered preventable<sup>6</sup>

The Medical Device Manufacturer (MDM), the Sterilizer Manufacturer (SM) and health care professionals (HCPs) each play a critical role in device reprocessing to **prevent the incidence of an SSI** 

Instrument validation that demonstrates effective sterilization of a particular medical device is critical for sterility assurance and patient safety




## Shared Responsibilities in Assuring Safe & Effective Sterilization

 Safety and quality standards for medical devices produced by the European Union require the MDM to determine and communicate how each medical device should be reprocessed<sup>7</sup>

The MDM collaborates with the SM (e.g. ASP) to test the instrument's performance, in line with exacting standards,<sup>8</sup> providing sterility assurance and ensuring material compatibility and functionality (including device wear and material evolution after reprocessing)

Following validation, the reprocessing method is approved by the MDM, who reflect this in its Instructions for Use (IFU)<sup>8,9</sup>

#### ASP plays a crucial role in ensuring effective sterilization and SSI prevention:



### Similarity Does Not Equal Compatibility

- Each sterilizer, even if using the same sterilant, uses a **distinct** combination of various parameters to achieve sterility assurance (e.g. concentration, exposure time, temperature)
- $\rightarrow$ This combination of parameters varies depending on the device(s) being reprocessed, and **must meet the claims' require**ments of that cycle
- $\rightarrow$ Given this variation, without instrument validation in collaboration with the MDM, an SM cannot assume sterility assurance for a medical device; each medical device must be thoroughly tested in line with exacting standards<sup>8</sup> to ensure the highest level of patient safety

Assuming that sterilizers which use the same sterilant provide sterility assurance risks inadequate sterilization and, ultimately, may put patients at risk of harm.


# - The STERRAD<sup>™</sup> Sterility Guide (SSG) -Provides the Difference Between Assumed and Assured

✓ The SSG is a reference database of devices that meet STERRAD<sup>™</sup> Systems sterility claims, with easy access to more than 23,000 individually validated listings from over 100 original manufacturers<sup>10</sup>

ASP works directly with MDMs to perform rigorous instrument validation, accounting for potential real-world variables and adhering to ISO 14937 exacting standards<sup>10</sup>

Keytakeaways

✓ Upon successful validation, every listing is approved and endorsed by the original MDM, making the SSG a trusted resource for up-to-date sterilization information<sup>10</sup>



Instrument validation in adherence with exacting standards, such as ISO 14937, is vital for sterility assurance

Assuming sterility assurance based on similarities with sterilizers which use the same sterilant, rather than instrument validation, risks inadequate sterilization and may put patients at risk of harm

The SSG is a trusted source of reprocessing information, with every listing having undergone rigorous validation, as well as approval by the original MDM, providing the difference between assumed and assured sterility

#### asp.com



ASP International GmbH, Zug **Branch** Bahnhofstrasse 2, Zug 6300, Switzerland ©ASP 2021. All Rights Reserved.

ADVANCED STERILIZATION PRODUCTS, INC. 33 Technology Drive, Irvine CA 92618, USA ASP, The Netherlands BV BIC 1, 5657 BX Eindhoven, The Netherlands REP

iew and modelling study. The Lancet Infectious Diseases 2015;15:1429-1437. 2. Agency for Hea er D. et al. Potential burden of antibiotic resist axis in the USA: a literature rev A, Gandra S, Sardra J, et al. Potential ourgent of antiootic resistance on surgery and cancer chemotrapy antiolotic prophysixis in the USA: a treature review and modelling study. In B Lancet Infectious Undesates 20 (1): 14:247-1437. 2 Agency fr and Quality 2013 Annual Hospital-Acquired Condition Rate and Estimates of Cost Savings and Deaths Averted From 2010 to 2013. Available from: https://www.ahrq.gov/sites/default/files/publications/files/hacrate2013.0. pdf [Accessed Novem J, Stewart M, Coulombe C, et al. Surgical site infections linked to contaminated surgical instruments. J Hosp Infect 2012;81:231-8. f. Tosh PK, Disbot M, Duffy JM, et al. Outbreak of Pseudomonas arength of hospitalization, and extra costs. Infect Control Hosp Diol Infect Control Hosp Epidemiol 2011;32:1179-86. S. Kirkland KB, Brigge JP. Trivette SL, et al. The impact of surgical-istic infections in the 1990s: attributable mortality. excess length of hospitalization, and extra costs. Infect Control Hos 25:-06. 6. European Centre for Disease Prevention and Control. Annual Epidemiological Report for 2015. Healthcare-associated infections in intensive care units. Available from: https://www.edc.gov/pa.eu/sites/default/files/docu-healthcare-associated-infections\_0.pdf (Accessed November 2020). 70 (Pficial Journal of the European Inclusion [Cl) 2017/7.65 of the European Parliament and of the Council of 5 April 2017. 8. International Organization for Standardization. ISO 17664:2017(en). 10. Advanced Sterilization Products. STERRADSterilityGuide.com. efault/files/publications/files/hacrate2013\_0.pdf [Accessed November 2020].